Results 11 to 20 of about 62,498 (301)
Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men [PDF]
Addiction and Health, 2018 Background: Buprenorphine sublingual tablets are now available in Iran for opioid detoxification in clinics. Aim of the present study was to compare the efficiency of buprenorphine with buprenorphine/naloxone in short-term detoxification in a group of ...
Hassan Ziaaddini +4 more
doaj +3 more sources
Journal of Opioid Management, 2018 A significant breakthrough in the treatment of opioid addiction occurred with the passage of the Data Addiction Treatment Act of 2000 (DATA 2000),1 signed into law by President Clinton, which allowed physicians for the first time in more than eight decades to prescribe opioid medications for the treatment of opioid addiction in the normal course of ...
Sidarth Wakhlu, MD
openaire +3 more sources
Buprenorphine – an attractive opioid with underutilized potential in treatment of chronic pain
Journal of Pain Research, 2015 Ish K Khanna, Sivaram PillarisettiNeuroPn Therapeutics, Alpharetta, GA, USAAbstract: Despite proven clinical utility, buprenorphine has not been used widely for the treatment of chronic pain.
Khanna IK, Pillarisetti S
doaj +1 more source
Acta Crystallographica Section E Structure Reports Online, 2014 In the crystal structure of a semi-synthetic opioid drug buprenorphine, C29H41NO4{systematic name: (2S)-2-[(5R,6R,7R,14S)-9α-cyclopropylmethyl-3-hydroxy-6-methoxy-4,5-epoxy-6,14-ethanomorphinan-7-yl]-3,3-dimethylbutan-2-ol}, the cyclopropylmethyl group is disordered over two sites with an occupancy factor of 0.611 (3) for the major component.
Jaroslaw Mazurek +4 more
+6 more sources
Transdermal buprenorphine for pain management in children [PDF]
, 2021 Pain is one of the main symptoms reported by sick children, particularly by those suffering from cancer. Opioids are very useful in controlling this symptom but they are burdened with significant side effects that limit their use in children ...
Ruggiero A. +8 more
core +1 more source
Managing opioid withdrawal precipitated by buprenorphine with buprenorphine [PDF]
Drug and Alcohol Review, 2021 AbstractBuprenorphine is a partial opioid agonist commonly used to treat opioid dependence. The pharmacology of buprenorphine increases the risk of a precipitated opioid withdrawal when commencing patients on buprenorphine treatment, particularly when transferring from long acting opioids (e.g. methadone).
Bridget Oakley +3 more
openaire +2 more sources
Safety of opioid patch initiation in Australian residential aged care [PDF]
, 2015 Explores opioid use by aged care facility residents before and after initiation of transdermal opioid patches. Abstract Objective: To explore opioid use by aged care facility residents before and after initiation of transdermal opioid patches. Design:
Lisa Pont +5 more
core +1 more source
Indian Journal of Anaesthesia, 2010 Neuraxial opioids provide excellent analgesia intraoperatively and postoperatively while allowing early ambulation of the patient by sparing sympathetic and motor nerves. A prospective, randomised double blind study was conducted involving 90 patients of
Shaloo Ipe +5 more
doaj +1 more source
Substance Abuse Treatment, Prevention, and Policy, 2022 Background and aims In the United States, access to buprenorphine remains low and disparities regarding who receives treatment have emerged. Federal laws have regulated buprenorphine delivery, ultimately limiting its implementation more broadly.
Barrot H. Lambdin +2 more
doaj +1 more source
Adapting low-dose buprenorphine induction to meet patient needs: A pilot study
Drug and Alcohol Dependence Reports, 2022 Introduction: Low-dose buprenorphine induction (LDBI) has been proposed to initiate buprenorphine in patients who are taking full opioid agonists in order to limit the risk of precipitated withdrawal.
Zoe A. Karavolis, Payel J. Roy
doaj +1 more source